Second Sight Medical Products (EYES) receives additional grant from National Institutes of Health (NIH) related to risks and benefits of visual neuroprostheses

What Happens With Second Sight Medical Products?

Second Sight Medical Products (EYES) announced today, Aug. 11, that the developer of implantable vision prostheses has received an additional grant from the National Institutes of Health (NIH) to fund a study collecting information on how blind people analyze the benefits and risks. visual neuroprostheses. During the extended hours of trading this morning, EYES shares rose 2.36%, to $ 3.90 per share.

What does this mean for the EYES?

The study, funded by the National Institutes of Health, will help Second Sight Medical Products “better understand the acceptable risks, the necessary benefits, and the appropriate risk / benefit balance for visual cortical prostheses, from the perspective of the target population. According to a company press release. The study is linked to the company’s Orion Visual Cortical Prosthesis System (Orion), which is an implanted cortical stimulation device designed to provide sight to people who are blind (for a variety of reasons).

The grant of $ 155,964 will be awarded to UCLA, which will act as a subcontractor to conduct the study. “The additional grant is tied to the $ 6.4 million NIH grant for the early feasibility clinical trial of a visual cortical prosthesis” stemming from promising Orion trial data reported by Second Sight in May 2021.

EYES has a Short Term Technical Rank of 27. Find out what that means to you and get the rest of the rank on EYES!

Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices to create an artificial form of vision useful for blind people. The company’s Argus II System product treats external retinal degeneration, such as retinitis pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China and whose main income comes from the United States.

Source link

Leave a Reply

Your email address will not be published.